For the quarter ending 2025-09-30, AEON had -$2,512K decrease in cash & cash equivalents over the period. -$2,596K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | -4,538 | 2,453 |
| Depreciation | 19 | 39 |
| Stock-based compensation expense | 414 | 3,311 |
| Loss on issuance of warrants | 0 | -75,644 |
| Change in fair value of convertible notes | -1,877 | -3,485 |
| Change in fair value of warrants | 237 | -86,187 |
| Change in fair value of contingent consideration | -37 | -3,472 |
| Prepaid expenses and other current assets | -338 | 245 |
| Accounts payable | -1,382 | -2,003 |
| Accrued expenses and other liabilities | 481 | -3,018 |
| Other assets and liabilities | 5 | 7 |
| Net cash used in operating activities | -2,596 | -10,000 |
| Purchases of property and equipment | 0 | 4 |
| Net cash used in investing activities | 0 | -4 |
| Proceeds from issuance of at-the-market shares, net | - | 84 |
| Proceeds from issuance of shares, net-At Market Offering | 168 | - |
| Proceeds from issuance of public offering shares, net | - | 18,346 |
| Proceeds from issuance of shares, net-Public Offering | 18,346 | - |
| Net cash provided by financing activities | 84 | 18,430 |
| Net increase (decrease) in cash | -2,512 | 8,426 |
| Cash and cash equivalents at beginning of period | 13 | - |
| Cash and cash equivalents at end of period | 5,927 | - |
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)